Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Pharmacogenetics (London)

• Publication date

  1998-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1097/00008571-199804000-00010PMID 10022755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Determination of dextromethorphan metabolizer phenotype in healthy volunteers

  2004cited by this paper
• Characterization of the 16+9 kb and 30+9 kb CYP2D6 XbaI haplotypes.

  1997cited by this paper
• Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

  1997cited by this paper
• Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

  1997cited by this paper
• Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

  1997cited by this paper
• Nomenclature for human CYP2D6 alleles.

  1996cited by this paper
• PCR-based genotyping for duplicated and deleted CYP2D6 genes.

  1996cited by this paper
• Ultrarapid metabolizers of debrisoquine: Characterization and PCR‐based detection of alleles with duplication of the CYP2D6 gene

  1996cited by this paper
• Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.

  1995cited by this paper
• Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles of CYP2D6 in a European Population

  1991cited by this paper
• Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

  1990cited by this paper
• Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

  1988cited by this paper

• How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

  2020cites this paper
• Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor

  2019cites this paper
• Clinical Pharmacogenomics Of Human Cyp2d6

  2018cites this paper
• A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third‐Generation Aromatase Inhibitors

  2017cites this paper
• Prediction and visualization of CYP2D6 genotype-based phenotype using clustering algorithms

  2017cites this paper
• Digital PCR for determination of cytochrome P450 2D6 and sulfotransferase 1A1 gene copy number variations.

  2017cites this paper
• Pharmacogenetic testing revisited: 5′ nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19

  2017cites this paper
• Association between the Severity of Tramadol Toxicity and Some CYP2D6 Allelic Variants in Egyptian Tramadol Intoxicated Patients

  2016cites this paper
• Clinical Applications of Pharmacogenomics in Cancer Therapy

  2016cites this paper
• Impact of Genetic Variability in CYP2D6, CYP3A5, and ABCB1 on Serum Concentrations of Quetiapine and N-desalkylquetiapine in Psychiatric Patients

  2015cites this paper
• CYP2D6: Where It All Began

  2015cites this paper
• Heritability of metoprolol and torsemide pharmacokinetics

  2015cites this paper
• Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis.

  2014cites this paper
• Erblichkeit in der Aktivität der Enzyme CYP2D6 und CYP2C9 sowie des Transporters OATP1B1 unter Berücksichtigung der bereits bekannten genetischen Varianten

  2014cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• Establishment of CYP2D6 Reference Samples by Multiple Validated Genotyping Platforms

  2014cites this paper
• Complexities of CYP2D6 gene analysis and interpretation

  2013cites this paper
• Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies

  2013cites this paper
• Pharmacokinetic behavior presents drug therapy challenges

  2013cites this paper
• Genetic polymorphism of CYP2D6 gene among Egyptian hypertensive cases

  2013cites this paper
• Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters.

  2012cites this paper
• Multi-ethnic Cytochrome-P450 Copy Number Profiling: Novel Pharmacogenetic Alleles and Mechanism of Copy Number Variation Formation

  2012cites this paper
• Pharmacogenomics of CYP 2 D 6 : Molecular Genetics , Interethnic Differences and Clinical Importance

  2012cites this paper
• Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.

  2012cites this paper
• Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients

  2011cites this paper
• Identification of New Alleles and the Determination of Alleles and Genotypes Frequencies at the CYP2D6 Gene in Emiratis

  2011cites this paper
• Pharmacogenetics of cytochrome P450 (CYP) in the elderly.

  2010cites this paper
• Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer.

  2010cites this paper
• High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases

  2010cites this paper
• Pharmacogenetics from a Forensic Perspective

  2009cites this paper
• The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

  2009cites this paper
• No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.

  2009influential citation
• Pharmacogenetics from a Forensic Perspective CYP2D6 and CYP2C19 genotype distributions in autopsy cases

  2009cites this paper
• Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): Population Distribution of CYP2D6 Activity

  2009influential citation
• Study on herb-drug interactions

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.

  2009cites this paper
• Clinical pharmacogenetics and potential application in personalized medicine.

  2008cites this paper
• Einfluss von Polymorphismen im CYP2D6 -Gen auf die klinischen Effekte einer Therapie mit Metoprolol: Eine prospektive longitudinale Doppelblindstudie.

  2008cites this paper
• Impact of CYP2D6*10 on recurrence‐free survival in breast cancer patients receiving adjuvant tamoxifen therapy

  2008cites this paper
• Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers

  2008cites this paper
• Hormonal Therapy for the Treatment of Postmenopausal Breast Cancer Patients

  2008cites this paper
• Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.

  2007cites this paper
• Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions?

  2007cites this paper
• Cytochrome P450 2D6 genotyping of fatal intoxications using Pyrosequencing

  2004cites this paper
• Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children

  2004cites this paper
• Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting

  2004cites this paper
• Chapter 13 - Applications of genotyping and phenotyping for clinically-relevant polymorphisms of drug metabolizing enzymes and drug transporters

  2004cites this paper
• Molecular diversity at the CYP2D6 locus in the Mediterranean region

  2004cites this paper
• Genetic polymorphisms of CYP1A1, CYP2D6, GSTM1, and GSTT1 and susceptibility to acute lymphoblastic leukemia in Indian children

  2004cites this paper
• Fatal intoxication cases: cytochrome P 450 2D6 and 2C19 genotype distributions

  2004cites this paper
• Cytochrome P 450 2 D 6 genotyping of fatal intoxications using Pyrosequencing

  2004cites this paper
• Human Liver Cytochrome P450 2D6 Genotype, Full‐length Messenger Ribonucleic Acid, and Activity Assessed with a Novel Cytochrome P450 2D6 Substrate

  2004cites this paper
• CYP2D6 Polymorphism and Tardive Dyskinesia in Schizophrenic Patients

  2003cites this paper
• Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships.

  2003cites this paper
• Bioinformatics research on inter-racial difference in drug metabolism II. Analysis on relationship between enzyme activities of CYP2D6 and CYP2C19 and their relevant genotypes.

  2003cites this paper
• Pharmacokinetics of Antidepressants and Lithium

  2003cites this paper
• Implications of pharmacogenetics for individualizing drug treatment and for study design

  2003cites this paper
• CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.

  2003cites this paper
• Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects

  2003influential citation
• Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects

  2002cites this paper
• Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability.

  2002cites this paper
• Therapy with Antidepressants: Pharmacogenetic Aspects

  2002cites this paper
• Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients

  2001cites this paper
• Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy.

  2001cites this paper
• Codeine phosphate in paediatric medicine.

  2001cites this paper
• CYP2D6 Genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting

  2000cites this paper
• Interethnic differences of drug-metabolizing enzymes.

  2000cites this paper
• Ethnic Differences in Drug Metabolism

  2000cites this paper
• Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR.

  2000cites this paper
• CYP2D6 gene polymorphism in caucasian smokers: lung cancer susceptibility and phenotype-genotype relationships.

  2000cites this paper
• Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

  2000cites this paper
• How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport

  2000cites this paper
• Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias.

  1999cites this paper
• Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population

  1999cites this paper
• Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.

  1999cites this paper
• Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.

  1999cites this paper
• High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data.

  1998cites this paper